BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eli Lilly and Company (LLY) CEO Says Company Keeping Animal Health Business


2/12/2013 7:27:06 AM

Eli Lilly and Co's chief executive said his company had no intention of following Pfizer's lead by spinning off or selling the company's lucrative Elanco animal health unit. "We're comfortable with that business and we're going to keep it," Lilly CEO John Lechleiter said definitively on Monday during a question and answer session at the BIO CEO & Investor conference in New York. Pfizer earlier this month spun off its animal health business through an initial public offering that raised $2.2 billion, though Pfizer will control roughly 80 percent of the new company, leading to speculation that other drugmakers would follow suit. But Lechleiter said his company was very happy with a business that was posting industry leading growth rates. He said livestock and pet care products now accounted for about 10 percent of total company sales, up from 5 percent to 6 percent a few years ago, and that the percentage could become even bigger. While overall sales at Lilly declined about 7 percent in 2012, primarily due to generic competition for its once top-selling Zyprexa schizophrenia drug, the animal health unit saw sales jump 21 percent to $2 billion, with a 30 percent rise in the United States. Lechleiter also said the company had no plans to make a push into so-called orphan drugs - medicines for serious conditions that affect few people but command astronomical prices. Many drugmakers have found this to be an attractive option as they try to find ways to make up for former big sellers facing generic competition.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->